Head & Neck Oncology Research in the Department of Otolaryngology
Clinical Investigations Core
Campus Box B-189
4200 East Ninth Avenue, Denver, CO 80262
Phone: (303) 372-9123 |
Clinical Trials by Disease Site - Head and Neck
H&N Clinical Trials Staff Members
- (Medical Oncology) Allen Cohn, MD (303) 315-8801
- (Surgery) Arlen Meyers, MD (720) 848-2820
- (Surgery) Nathan Pearlman, MD (303) 315-8671
- (Radiation Oncology) Michael Weil, MD (303) 315-7819
- (Clinical Research Associate) Lynda Peterson, RN (303) 372-9106
|
Head and Neck - Chemoprevention
SWOG 9446/95-271. RTOG 91-15. Chemoprevention Trial to Prevent Second Primary Tumors with Low-Dose 13-Cis Retinoic Acid in Head and Neck Cancer.
Stage I, II
16 wk to 3 yrs after surgery and/or RT
Limited to oral cavity, pharynx & larynxI: 13-CRA;
II: PlaceboUntreated
NED
Phase II
IRB 08/08/95
DGH
Click here to view the protocol Abstract (a link to the SWOG web site) |
Head and Neck, Resectable
SWOG 9515/96-030. RTOG 95-01. Cytom 8855/91-364. Phase III Intergroup Trial of Surgery Followed by (1) Radiotherapy versus (2) Radiochemotherapy for Resectable High Risk Squamous Cell Carcinoma of the Head and Neck
Post Surgery
I: RT
II: RT + CDDP
Untreated
NED
Phase III
IRB 2/8/96
Click here to view the protocol Abstract (a link to the SWOG web site) |
Head and Neck
97-555 Cohn. A Phase II Multi-Center, Open-Label, Study to Evaulate Effectiveness and Safety of Ad5CMV-p53 Administered by Intra-Tumoral Injections in 39 Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Recurrent Squamous Cell Following First Line Therapy; lesions accessible to injection; no CNS mets.
I: Ad5CMV-p53
Treated; > 4 weeks after RT
Measurable
Phase II
IRB 2/5/98 |
Head and Neck, Laryngeal
SWOG 9201/92-437 (NCI HIGH PRIORITY). RTOG 91-11. Cytol. 8855/91-364. RTOG 94-18. Phase III Trial to Preserve the Larynx: Induction Chemotherapy and Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy Versus Radiation.
Stages III and IV
I: CDDP/5FU; RT
II: RT/CDDP
III: RT
Untreated
NED
Phase III
IRB 12/10/92
(DHMC)
*Spanish Version Consent Available*
Click here to view the protocol Abstract (a link to the SWOG web site) |
SWOG 9709/97. A Phase II Study to Evaluate Transoral CO2 Laser Supraglottic Laryngectomy and Irradiation in Stage I, II and III Squamous Cell Carcinoma of the Supraglottic Larynx.
Stage I, II and III (T1-2, N1, M0)
Supraglottic larynx
I: CO2 laser surgery + neck dissection + R T
Untreated
Measurable
Phase II
IRB |
Head and Neck, Advanced
92-273 Cohn. Phase II Study of Alternating Chemotherapy and Accelerated Hyperfractionated Radiation Therapy in Patients With Advanced Cancer of the Head and Neck.
I: CBDCA + 5-FU Alternating with hyperfractionated RT
Untreated
Measurable
Phase II
IRB 08/04/92
(DHMC)
Contact: Eileen Marks 303-315-7819
(DHMC) |
SWOG 9059/92-308. Cytom 8855/91-364.Phase III Comparison of Standard Radiotherapy, versus Radiotherapy plus Simultaneous Cisplatin, versus Split-Course Radiotherapy Plus Simultaneous Cisplatin and 5-Fluorouracil, In Patients with Unresectable Squamous Cell Carcinoma of the Head and Neck.
I: RT
II: RT + CDDP
III: (split course) RT + CDDP + 5FU
Untreated
Meas/Eval
Phase III
IRB 09/08/92
(DHMC)
Click here to view the protocol Abstract (a link to the SWOG web site) |
SWOG 9708/97-714. Evaluation of Gemcitabine (Gemzar) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
I: Gemcitabine
Untreated for recurrence
Measurable
Phase II
IRB 2/3/98
(DHMC) |
